Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 22:16:379-392.
doi: 10.2147/BCTT.S460856. eCollection 2024.

Brain Radiotherapy Combined with Targeted Therapy for HER2-Positive Breast Cancer Patients with Brain Metastases

Lifeng Tang  1   2 , Wei Zhang  3 , Long Chen  2
Affiliations

Brain Radiotherapy Combined with Targeted Therapy for HER2-Positive Breast Cancer Patients with Brain Metastases

Lifeng Tang et al. Breast Cancer (Dove Med Press). .

Abstract

Background: Research on the sequencing of brain radiotherapy and targeted chemotherapy after brain metastasis (BM) in HER2-positive breast cancer patients is limited and inconclusive. This study investigated the efficacy of sequential delivery of radiotherapy and targeted therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with BM.

Methods: Fifty-seven patients were categorized into two groups: the targeted-radiotherapy group (receiving 2-8 cycles of anti-HER2-targeted therapy followed by radiotherapy after BM) and the radiotherapy-targeted group (undergoing radiotherapy first, followed by regular anti-HER2-targeted therapy). The study endpoints were intracranial progression-free survival (iPFS) and overall survival. Factors associated with intracranial progression and mortality were assessed by univariate and multivariate Cox proportional hazards analysis.

Results: Patients in the radiotherapy-targeted group had better iPFS (P < 0.001), while there was no significant difference in overall survival between the two groups (P = 0.145). Multivariate Cox analysis showed that different sequential treatment groups were independent prognostic factors for iPFS. In patients with a modified breast graded prognostic assessment score of 3.5-4.0, the median survival time was 26 months in the radiotherapy-targeted group and 22 months in the targeted-radiotherapy group (P = 0.019).

Conclusion: Overall, radiotherapy followed by targeted therapy may improve survival in HER2-positive breast cancer patients with BM, particularly in those with a modified breast graded prognostic assessment score of 3.5-4.0.

Keywords: HER2; HER2-targeted drugs; brain metastasis; breast cancer; craniocerebral radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest for this work.

Figures

Figure 1
Figure 1
Flow chart of patients included in the study.
Figure 2
Figure 2
Magnetic Resonance Imaging (MRI) for breast cancer combined with brain metastasis in a 45-year-old female patient. T1WI revealed an irregular hypointense nodule in the right precentral gyrus; T2WI showed a slightly hyperintense signal; T2Flair demonstrated a hyperintense signal; and T1-CE displayed significant enhancement of the lesion.
Figure 3
Figure 3
Magnetic Resonance Imaging (MRI) for breast cancer combined with brain metastasis in a 50-year-old female patient. T1WI revealed an irregular hypointense nodule in the cerebellar vermis; T2WI and T2Flair showed slightly hyperintense signals; diffusion-weighted imaging (DWI) presented an isointense signal; the mean apparent diffusion coefficient (ADC) value of the lesions was 0.813 x 10(-3) mm²/s; and T1-CE demonstrated significant enhancement of the lesion.
Figure 4
Figure 4
Kaplan-Meier analysis comparing intracranial progression-free survival (a) and overall survival (b) in the radiotherapy-targeted group and the targeted-radiotherapy group.
Figure 5
Figure 5
Kaplan-Meier overall survival curves for modified breast graded prognostic assessment 2.0–3.0 group (a) and 3.5–4.0 group (b) in the radiotherapy-group and the targeted-radiotherapy group.
Figure 6
Figure 6
Kaplan-Meier overall survival curves for modified breast graded prognostic assessment scores in the radiotherapy-targeted group and the targeted-radiotherapy group.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660 - DOI - PubMed
    1. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983;52(12):2349–2354. doi:10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B - DOI - PubMed
    1. Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Goncalves A. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012;32(11):4655–4662. - PubMed
    1. Yardley DA, Kaufman PA, Huang W, et al. Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter collaborative biomarker study and correlation with overall survival. Breast Cancer Res. 2015;17(1):41. doi:10.1186/s13058-015-0543-x - DOI - PMC - PubMed
    1. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006;17(6):935–944. doi:10.1093/annonc/mdl064 - DOI - PubMed